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Abstract
Background/Aims: Arterial hypertension is characterized by vascular remodelling, 
atherosclerosis and cardiovascular complications. Matrix metalloproteases (MPPs) are 
endopeptidases produced by all the cells present in the vascular wall and are involved in 
the regulation of the extracellular matrix protein turnover. MMPs contribute to blood vessel 
formation, remodelling, angiogenesis; whereas an altered expression or activity of MMPs or 
their tissue inhibitors (TIMPs) results correlated with the development and progression of 
cardiovascular complications. Methods: We examined the literature data regarding the role of 
MMPs in human hypertension, including their involvement in vascular remodelling, and the 
effects of some antihypertensive molecules on these MMP/TIMP profile. Results: The expression 
and the activity of some MMPs and TIMPs are impaired in human hypertension. An altered 
MMPs/TIMPs balance plays an mportant role in the vascular wall rearrangement, in response 
to hemodynamic changes which may induce myocardial hypertrophy and fibrosis leading to 
ventricular remodelling. Several studies have examined the effects of some antihypertensive 
molecules, such as ACE inhibitors, angiotensin receptor blockers, calcium-channel blockers, 
and aldosterone antagonists, on the MMPs/TIMPs profile by obtaining positive results. 
Conclusion: Considering the data taken into consideration, the authors believe that in clinical 
practice a strategic antihypertensive therapy directed to the MMPs profile, may be useful to 
decrease the risk of cardiovascular complications.
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IntroductionArterial hypertension is associated with vascular remodelling characterized by a rearrangement of vascular wall components, including extracellular matrix (ECM) protein, 
such as elastin and collagen fibres. Reciprocal interaction between vascular cells and their ECM 
is pivotal in blood vessel formation and remodelling [1]. Hypertensive vascular remodelling is an adaptive response to changes in the blood-pressure-induced circumferential wall stress 
and blood-flow-induced wall shear stress, which result in the degradation and reorganization 
of the vascular ECM protein, such as collagen, elastin, proteoglycan and fibronectin [2, 3].Matrix metalloproteinases (MMPs) are a large variety of endopeptidases involved in 
ECM protein degradation by cleavage of internal peptide bonds. Each MMP has a specific 
substrate target that defines its denomination, such as collagenase, gelatinase, stromelysin 
and matrilysin.
Collagenases (MMP-1, -8, -13, and -18) cleave interstitial collagen I, II, and III, and 
also other molecules, such as bradykinin and angiotensin I. Fragments of collagen are 
then degraded by gelatinases [4]: MMP-2 and -9 are secreted by several vascular cell 
types, including endothelial cells, pericytes and podocytes, fibroblasts and myofibroblasts, 
monocyte derived macrophages and local macrophages tissue [5]. They are responsible 
for IV type collagen degradation, vasculature remodelling, angiogenesis, inflammation and 
atherosclerotic plaque rupture [6, 7]. MMP-2 is constitutively expressed on cell surface, 
while MMP-9 is stored in secretory granules in different cell types and it is inducible by 
exogenous stimuli [5, 8]. Stromelysin-1 (MMP-3) and -2 (MMP-10) degrade the fibronectin, 
laminin, gelatins-I, III, IV and V, collagen fibers, and proteoglycans [6]. Matrilysins may 
hydrolize fibronectin, gelatins [6] and may cleave plasminogen producing a fragment 
that inhibits angiogenesis. Membrane-Type MMPs (MT-MMPs), transmembrane or GPI 
(glycosylphosphatidylinositol)-anchored, can degrade type-I, -II, and III collagen and other 
components of ECM [4]. The regulation of MMPs synthesis and activity is highly complex. 
Radical oxygen species (ROS), growth factors, cytokines and hormones can influence MMP transcription through the activation of the Mitogen-Activated Protein Kinase (MAPK), the inhibition of MAPK phosphatase, the inactivation of the histone deacetylase (involved in 
gene repression) or the recruitment of different chromatin remodelling factors [9].Most of the MMPs are synthesized as precursors (pro-MMP) and must be activated to expose the catalytic domain with the Zn2+–binding site. This activation can be effected by 
proteolytic modifications from several proteases [8,10] and also by S-glutathiolation, S-ni-trosylation and phosphoryla-
tion reactions [11, 12] (Fig. 1).
In experimental models, some authors have demon-
strated that angiotensin II could promote the expres-
sion of MMP-8 and MMP-13 by macrophages and their activity in atherosclerotic 
plaques [13], while others 
have highlighted that MMP-2 
mediates angiotensin II-in-duced hypertension, being transcriptionally regulated by MMP-7 and by a disin-tegrin and metalloproteas-
es (ADAM-17) [14]. On the contrary, MMPs activity can be underegulated by several Fig. 1. Regulation of MMPs synthesis and activity.
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proteins, such as alpha2-macroglobulin, β-amiloid precursor protein and GPI-anchored gly-
coprotein, and by the four tissue inhibitors of MMP (TIMPs): TIMP-1 acts on MMP-1, MMP-
3, MMP-7 and MMP-9; TIMP-2 inhibits especially MMP-2; TIMP-3 can inhibit MMP-2 and 
MMP-9; TIMP-4 inhibits MT-1 MMP and MMP-2 activity [8, 15] (Fig. 1). TIMPs activities in-clude regulation of cell proliferation, migration and invasion, anti-angiogenesis and apopto-
sis [16]. Most of these activities arise from MMP inhibition, but TIMPs are also able to inter-
act with some specific cell receptors; for example, TIMP-3 binds vascular endothelial growth 
factor (VEGF) receptor on endothelial cells inhibiting angiogenesis [16].MMPs contribute to the remodelling of basement membranes and the degradation of the components of the ECM and are involved in angiogenesis and in vascular smooth muscle 
cells contraction [4].MMPs participate not only to the development of atherosclerosis, but also in its progression and in its complication: an increased MMP expression has been detected in atherosclerotic plaques and their activity may be responsible for plaque instability and 
rupture, and for an increased platelet aggregation [4].
Previously, we evaluated the behaviour of MMPs and TIMPs in metabolic syndrome and in obstructive sleep apnea syndrome, both conditions associated with arterial hypertension 
and with an elevated cardiovascular risk [17-21]. Considering that in the last decades several papers have focused on the role of MMPs and their inhibitors in arterial hypertension 
[22-26], our aim was to examine the literature data regarding their role in human hypertension and its complications, and the effects of some antihypertensive molecules on the MMP/
TIMP profile. Some authors have underlined that elevated levels of MMP-9 and TIMP-1 
actually preceed the occurance of hypertension. By examining a population of participants 
to the Framingham Offspring Study, Dhingra et al have observed that subjects with higher 
TIMP-1 had more than double the possibility of having a hypertension occurance. In addition, 
there is a high risk to switch to a higher blood pressure classification, such as subjects with 
detectable concentration of MMP-9 [27].
MMPs and hypertension-induced vascular remodellingChanges in blood pressure are responsible for different kinds of mechanical forces applied to the arterial wall: the thin wall hoop stress in the circumferential direction, the 
wall shear stress developed by blood flow and the axial stress induced by elongation in the 
axial direction. In response to these changes, the arterial vessels modify their thickness, 
composition and elastic properties [29]. Physiologically, vascular remodelling is an adaptive phenomenon of the circulatory system to changes in hemodynamic or metabolic demands, but chronically it contributes 
to atherosclerosis development and cardiovascular complications. The inward eutrophic remodelling is usually observed in resistance arteries in the early stages of hypertension, which is characterized by a reduction of the vessel lumen with normal media thickness and 
a rearrangement of vascular smooth muscle cells (VSMCs) [30, 31]. The renin-angiotensin 
system plays a pivotal role in vascular remodelling: angiotensin II has some effects on 
vascular fibroblast proliferation, ECM protein production and adhesion to matrix proteins. 
The hypertrophic remodelling is associated with an increase in the arterial wall thickness characterized by collagen deposition and elastin degradation, it is also common in large 
arteries, such as the aorta, in chronic severe hypertension [2].
MMPs play a specific role in blood vessel formation, remodelling and angiogenesis; moreover there are also some stimuli which induce MMPs expression and activation, such as 
oxidative stress, inflammation, angiotensin II, and hemodynamic forces [32] (Fig. 2).
In the vascular wall of hypertensive subjects, there is an accelerated turnover and depo-
sition of ECM components, mostly induced by MMPs. In addition, MMPs cleave large endothe-
lin molecule producing smaller vasoactive fragments with a consequent activation of VSMCs 
and vasoconstriction [30]. Blood samples, of hypertensive subjects with atherosclerosis, 
show elevated levels of MMP-9 mRNA, whereas similar levels of TIMP-1 mRNA were found in 
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Doppler indices of diastolic dysfunction [38]. Similarly, Ahmed et al have found an increased 
MMP-9 and TIMP-1 concentration in subjects with left ventricular hypertrophy and higher 
levels of TIMP-1 in those with chronic heart failure (CHF) [39]. TIMP-1 seems to be correlat-ed to left ventricular mass and to the diastolic dysfunction degree (evaluated as mitral E/A 
ratio) [39, 40]. Recently, Ikonomidis et al have observed that the elevated levels of MMP-9 
and TIMP-1 in hypertensive subjects are related to an impaired systolic myocardial deforma-
tion and to an increased arterial stiffness, evaluated as PWV [41]. Probably, an attenuation of the proteolytic activity of the MMPs, mediated by the elevated levels of tissue inhibitor, produces an accumulation of ECM proteins and, in particular, an increase in collagen content 
contributing to the development of the hypertensive heart disease (Fig. 3).
Some authors have suggested that an increase in MMP-9, TIMP-1, and in MMP-7 levels could predict the presence of left ventricular hypertrophy, while an increase in 
Fig. 3. Possible role of MMPs in cardiac remodelling in arterial hy-
pertension.
Fig. 2. Possible role of MMPs in vascular remodelling in arterial hy-
pertension.
comparison with normotensive 
or hypertensive subjects with-
out atherosclerosis [33]. Tan et al demonstrated an increased 
concentration of MMP-9 and 
also of TIMP-1 in hypertensive 
subjects, positively correlat-ed with carotid-femoral pulse 
wave velocity (PWV), but not 
with carotid-radial PWV [34]. 
This evidence suggested an 
implication of MMP-9 and its inhibitor in large arteries stiff-ness, but not in small muscular 
arterial elasticity [34]. Howev-
er, MMP-9 polymorphisms are 
associated with higher MMP-9 levels, isolated systolic arterial 
hypertension [35] and carot-id-femoral pulse wave velocity 
[36].
MMPs and hyperten-
sion-induced cardiac re-
modelling
Franz et al have examined 
hypertensive subjects with left ventricular hypertrophy ob-
serving higher levels of TIMP-
1, TIMP-2 and TIMP-4 com-pared to controls, but also ele-
vated MMP-9 levels, especially in concentric hypertrophy 
[37]. Saglam et al have demon-strated higher levels of MMP-
3 and MMP-9 concentrations 
in hypertensive subjects with ventricular hypertrophy and a statistical correlation of these MMPs with left ventricular posterior wall thickness and 
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MMP-2 and a decrease in MMP-8 could predict 
the presence of diastolic heart failure [42]. Late-ly, the metanalysis of Marchesi et al has demon-
strated elevated concentrations of MMP-9 and 
TIMP-1 in hypertensive subjects without heart 
failure and elevated levels of MMP-2 in hyperten-sives with heart failure, suggesting a role of the 
MMP-2 in left ventricular remodelling [28]. In 
animal models, active myocardial MMP-2 expres-sion induces morphological alteration, such as 
myocyte hyperthrophy, myofilament lysis, sarco-
meres destruction and cardiac fibroblast prolif-
eration, resulting in ventricular remodelling [43].
In hypertensive subjects with paroxysmal 
atrial fibrillation, higher concentrations of TIMP-
Table 1. Antihypertensive drugs acting on 
MMPs/TIMPs profile in humans
1 are correlated to an increased thickness of interventricular septum, to an increase in left ventricular mass index and to combined concentric and eccentric ventricular hypertrophy, 
which is prognostically unfavourable [44]. Even the TIMP-2 polymorphisms are significantly 
associated with the development of atrial fibrillation in subjects with hypertensive heart 
disease; a decreased expression of TIMP-2 may be responsible for an abnormal deposition of 
extracellular matrix, atrial fibrosis and structural remodelling promoting arrhythmias [45].
MMPs and antihypertensive moleculesMany researches have described how some antihypertensive drugs may regulate 
the MMP activity and concentration. These drugs include angiotensin converting enzyme 
(ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers and some 
diuretics [46] (Table 1).
ACE inhibitors and angiotensin receptor blockers
ACE inhibitors and ARBs show antioxidant effects [47-50]. Recently, several studies 
have examined the influence of these molecules on the MMP/TIMP profile in vivo, keeping 
in mind the results obtained in experimental models. In fact, in vitro both the ACE inhibitor 
temocaprilat and the ARB olmesartan inhibited not only the AGE-induced ROS generation but 
also the MMP-9 expression and activity in cultured smooth muscle cells and in monocyte-
derived macrophages [51]. In samples of carotid artery from spontaneously hypertensive 
rats (SHR), a chronic treatment with a home-made ACE inhibitor reduced the expression 
of MMP-2 and MMP-9 and of inflammatory cytokines, such as IL-6 and TNF-α [52]. In the 
kidney of SHRs, the use of lisinopril or valsartan in monotherapy, or in combination, reduced 
the mRNA expression of TIMP-1 and MMP-9 [53]. In aortic VSMCs of Wistar rats, angiotensin 
II induced the expression of MMP-9, while losartan inhibited the expression of MMP-9 
while enhancing that of TIMP-1 with a consequent decrease in MMP-9/TIMP-1 ratio in a 
concentration-dependent manner [54]. In addition, in SHR the renin inhibition with aliskiren 
reduced the myocardial expression of gelatinases and TIMP-1 after an ischemia/reperfusion 
injury attenuating the myocardial damage [55].
In a group of 35 hypertensive subjects, Fontana et al have  noted  no effects after a 8 week enalapril treatment on plasma levels and activity of MMP-2, MMP-9, MMP-8 and their 
inhibitors [56]. Derosa et al, in a cohort of subjects with arterial hypertension, have obtained 
a reduction in MMP-2 and MMP-9 concentrations after 13 months of losartan therapy, but the same result was not reached in ramipril-treated patients [57]. Differently, a 3 months period of anti-hypertensive treatment with lisinopril normalizes MMP-9/TIMP-1 ratio 
produced a reduction of plasma MMP-9 and an increase in TIMP-1 values, as well as in the use of candesartan [58].
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The effects of ACE inhibitors and ARBs have been examined also in hypertensive 
subjects with cardiovascular complications. Schieffer et al have observed an improvement 
of MMP-9/TIMP-1 ratio in subjects with coronary artery disease treated with irbesartan or 
enalapril [59].
Hypertensive subjects with a high-degree of internal carotid artery stenosis, treated with irbesartan for 4 months, presented a reduced expression of MMP-2 and MMP-9 in the 
plaque areas of intense macrophage infiltration and a decreased inflammatory reaction [60]. 
The authors have suggested that the effect of irbesartan on plaque stabilization could be 
mediated by the inhibition of macrophages activity and the reduction of the oxidative stress. 
Other authors have demonstrated that a treatment with irbesartan reduced also the levels of 
collagenases MMP-1 and MMP-8 in subjects with high-degree carotid stenosis, but increased elastin degradation, indicating that the MMPs are not involved in elastin degradation of the 
atheroma [61].
The effects of ACE inhibitors and ARBs on MMPs levels seem to be mediated by different 
mechanisms: the inhibition of angiotensin II activity on MMPs expression, the antioxidant 
and anti-inflammatory effects. In addition, Yamamoto et al demonstrated that ACE inhibitors 
bind the active site of MMP-9 decreasing its activity [62, 63].
Calcium channel blockers (CCBs)Animal models (rats) with renovascular hypertension treated with nifedipine, nimodipine, or amlodipine present a reduction of the oxidative stress and MMP-2 expression in thoracic 
aorta, inhibiting the vascular remodelling [64]. Similarly, a therapy with amlodipine and 
atorvastatin suppressed MMP-2 activity in the aorta of mice infused with angiotensin II for a 
period of 28 days [65]. It has been suggested that amlodipine decreases MMP-2 expression 
through the protein tyrosin kinase pathway [66]. Nifedipine and lercanidipine suppress 
the expression of inducible nitric oxide synthase mRNA, attenuate the TNF-α production 
and decrease the MMP-2, and MMP-9 expression and activity in VSMCs of rats treated with 
inflammatory stimuli [67]. In hypertensive rats, a treatment with nifedipine for 9 or 12 weeks 
reduced MMP-2 activity, left ventricular remodelling and cardiac dysfunction, independently 
of its antihypertensive action [68]. Lercanidipine promoted similar effects in diabetic rats 
[69]. In human macrophages treated with lacidipine for 24 hours, an evident decrease in 
MMP-9 and TIMP-1 expression has been observed [70].
In a group of hypertensive subjects, Martinez et al have demonstrated that the treatment with lercanidipine reduced MMP-9 plasma concentrations without affecting TIMP-1 or MMP-
2 levels [71]. In 48 hypertensive subjects treated with olmesartan, the combination therapy with azelnidipine induced a  reduction in MMP-2 levels and improved the arterial stiffness, differently from indapamide [72]. Azelnidipine seems to reduce the MMP-2 and MMP-9 gene 
expression as a pleiotropic antinflammatory effect, as it inhibits the macrophage infiltration 
into the vascular wall and the expression of proinflammatory cytokines [73]. Derosa et al 
have examined a group of 151 hypertensive subjects treated with losartan in combination with barnidipine or lercanidipine; both the CCBs have a slight reduction of MMP-2 and MMP-
9 plasma levels, even if the decrease was not statistically evident [74]. However, Nakamura et al have demonstrated that telmisartan, but not amlodipine reduced MMP-9 levels in 
hypertensive subjects with chronic renal failure, suggesting that ARBs are more effective in 
this kind of patients [75].
DiureticsCeron et al [76] have studied the effects on animal models with renovascular hypertension, after a combined treatment with hydrochlorothiazide and spironolactone on MMP activity 
and vascular remodelling. They observed that the treatment with the two molecules, or the 
combination of the two, induced antioxidant effects and attenuated MMP-2 up-regulation. 
They suggested that the antioxidant action of the diuretics was due to the direct inhibition 
of vascular NADPH oxidase activity [76]. In animal models with hypertensive heart failure, 
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